Lewy Body Disease - Pipeline Insight, 2024

This “Lewy Body Disease- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Lewy Body Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Lewy Body Disease: Understanding

Lewy Body Disease: Overview

Lewy Body Disease is caused by the degeneration and death of nerve cells in the brain. The name comes from the presence of abnormal spherical structures, called Lewy bodies, which develop inside nerve cells. It is thought that these may contribute to the death of the brain cells. They are named after the doctor who first wrote about them. It is sometimes referred to as Diffuse Lewy Body Disease. At present there is no known cause of Lewy Body Disease, and no known risk factors have been identified. There is no evidence that it is an inherited disease. This type of dementia is diagnosed by taking a careful history of the pattern of symptoms, and by excluding other possible causes such as vascular dementia and Alzheimer's disease. A brain scan may reveal brain degeneration, but the Lewy bodies can only be identified by examination of brain tissue after death. At present there is no cure for Lewy Body Disease.

Symptoms such as depression and disturbing hallucinations can usually be reduced by medication. However, medications to relieve hallucinations may increase muscle tremors and stiffness. Conversely, anti-Parkinson drugs may make hallucinations worse. Other symptoms include movement disorders, poor regulation of body functions, cognitive problems, and trouble with sleep, varying attention, and depression.

People who are diagnosed with Lewy body dementia have a gradual decline in the ability to think. No single test can diagnose Lewy body dementia. The diagnosis is based on symptoms and by ruling out other conditions. Tests might include: Neurological and physical exam A neurological exam tests; reflexes, strength, walking, muscle tone, eye movements, balance, sense of touch and assessment of mental abilities, blood tests and brain scans, sleep evaluation, heart test, and emerging biomarkers.

Treatment plan of disease there's no cure for Lewy body dementia, but many of the symptoms can improve with targeted treatments. Medications include Cholinesterase inhibitors these Alzheimer's disease medicines work by increasing the levels of chemical messengers in the brain, known as neurotransmitters, Parkinson's disease medicines. Medicines such as carbidopa-levodopa (Sinemet, Duopa, others) can help reduce rigid muscles and slow movement. Certain medicines can worsen memory. Therapies antipsychotic medicines can worsen Lewy body dementia symptoms. It might be helpful to first try other approaches, such as: Tolerating the behavior. Some people with Lewy body dementia aren't distressed by the hallucinations. Modifying the environment and reducing clutter and noise can make it easier for someone with dementia to function and lastly by creating daily routines and keeping tasks simple break tasks into easier steps and focus on successes, not failures. Structure and routine during the day can be less confusing.

Lewy Body Disease- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lewy Body Disease pipeline landscape is provided which includes the disease overview and Lewy Body Disease treatment guidelines. The assessment part of the report embraces, in depth Lewy Body Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lewy Body Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Lewy Body Disease R&D. The therapies under development are focused on novel approaches to treat/improve Lewy Body Disease.

Lewy Body Disease Emerging Drugs Chapters

This segment of the Lewy Body Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lewy Body Disease Emerging Drugs

Buntanetap: Annovis BioBuntanetap (previously known as ANVS401 or Posiphen) is a translational inhibitor of neurotoxic aggregating proteins (TINAPs). Buntanetap is an orally available small molecule, and its unique mechanism of action allows it to inhibit multiple neurotoxic proteins at once. Recent research has shown that multiple neurotoxic proteins are at play in all neurodegenerative diseases. Buntanetap, thus, offers a transformative and superior mechanism to treat neurodegenerative disorders. It’s being developed for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions such as Alzheimer’s in Down syndrome. Currently, the drug is in Phase II stage of its development for the treatment of Lewy body disease.

Neflamapimod: CervoMed, IncNeflamapimod is an investigational drug that is a brain-penetrant, oral small molecule that inhibits the intra-cellular enzyme p38 MAP kinase alpha (p38a). P38a, which is expressed in neurons under conditions of stress and disease, plays a major role in inflammation-induced synaptic toxicity, leading to impairment of synaptic function. Ne?amapimod targets and inhibits p38 alpha, a cellular enzyme linked to the in?ammation and synaptic dysfunction that cause neurological disease progression. Currently, the drug is in Phase II stage of its development for the treatment of Lewy body disease.

UB 312: VaxxinityUB 312 targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson’s and other synucleinopathies, such as dementia with Lewy Body (“DLB”) and multiple system atrophy (“MSA”). The first part of a Phase 1 trial in healthy volunteers has shown UB-312 to be well tolerated, with no significant safety findings, and immunogenic, with a high responder rate and antibodies that cross the blood-brain barrier (“BBB”). Currently, the drug is in Phase I stage of its development for the treatment of Lewy body disease.

Lewy Body Disease: Therapeutic Assessment

This segment of the report provides insights about the different Lewy Body Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Lewy Body Disease

• There are approx. 10+ key companies which are developing the therapies for Lewy Body Disease. The companies which have their Lewy Body Disease drug candidates in the most advanced stage, i.e. phase III include, Annovis Bio.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Lewy Body Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lewy Body Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lewy Body Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lewy Body Disease drugs.

Lewy Body Disease Report Insights

• Lewy Body Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lewy Body Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Lewy Body Disease drugs?
• How many Lewy Body Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lewy Body Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lewy Body Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lewy Body Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Annovis Bio
• CervoMed, Inc
• Vaxxinity
• Eisai Inc.
• Cognition Therapeutics
• Eli Lilly and Company
• Athira Pharma
• NLS Pharmaceutics

Key Products

• Buntanetap
• Neflamapimod
• UB 312
• E2027
• CT1812
• LY3154207
• ATH-1017
• Oxafuramine

This product will be delivered within 2 business days.